Pharmaplan and TRIPLAN move into the future together
“The names TRIPLAN and PHARMAPLAN stand for excellent engineering culture, which we want to further develop together with our employees in a quality-oriented manner. PHARMAPLAN and TRIPLAN should also act as attractive employers in the top league”, Dr. Andreas Bonhoff, CFO of TRIPLAN AG.
TTP AG, Frankfurt/Main, and its subsidiary TTP GmbH, have concluded an agreement with the Danish company NNE A/S, Copenhagen, for the acquisition of three NNE subsidiaries based in Switzerland, Germany and Belgium.
TTP AG is an operating holding company specializing in production-related engineering services for the process industry. It is the main shareholder of TRIPLAN Aktiengesellschaft, based in Bad Soden am Taunus, an engineering services company specializing in the life science, chemical and petrochemical industries. NNE specializes in engineering and consulting services in the growth markets of biotechnology and pharmaceuticals and covers all service areas for EPCM projects (Engineering, Procurement, Construction Management).
TTP AG plans to continue to manage the three NNE subsidiaries as largely independent companies in the pharmaceutical and life science sector and to revive the brand name PHARMAPLAN, under which the companies were managed until 2017.
Joachim Grendel, CEO of TTP AG: “The local presence, expertise, business areas and value chains of TRIPLAN and those of the future PHARMAPLAN complement each other perfectly. The combination will create one of the leading medium-sized engineering companies for the process industry in Europe.”
The acquisition is expected to take effect at the end of March 2019. The parties have agreed not to disclose the purchase price. The NNE companies in Germany, Switzerland and Belgium employ 360 people and generated sales of EUR 61 million in 2018. TRIPLAN is active in Germany, Switzerland and India and employs 420 people with a consolidated annual turnover of EUR 47 million in 2018.
